Physician profile
Anthony Infantolino
NPI 1164481032
$31,643.84
in general payments reported to CMS, 2019-2025
25 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $8,755 · 2021: $995 · 2022: $1,062 · 2023: $8,470 · 2024: $9,130 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,536 · Travel and Lodging: $3,965 · Consulting Fee: $3,880 · Food and Beverage: $3,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,536.00 |
| Travel and Lodging | $3,965.06 |
| Consulting Fee | $3,880.00 |
| Food and Beverage | $3,002.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19,273.33 | 2021-2025 | Gi Genius, Barrx, Pillcam |
| Covidien Lp | $8,963.93 | 2019-2020 | |
| Fujifilm Healthcare Americas Corporation | $1,182.09 | 2020-2025 | Fujifilm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,000.00 | 2019 | |
| Boston Scientific Corporation | $174.06 | 2019-2024 | Acquire, Exalt Model D |
| Celgene Corporation | $135.41 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $125.55 | 2023-2024 | Entyvio, Eohilia, Gattex |
| Endogastric Solutions, INC | $111.80 | 2023 | Esophyx |
| Regeneron Healthcare Solutions, INC. | $90.88 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $83.98 | 2023-2024 | Stelara, Simponi, Tremfya |
| Conmed Corporation | $79.62 | 2022 | |
| Apollo Endosurgery US INC | $77.52 | 2022 | |
| Erbe USA INC | $70.00 | 2024 | |
| Ironwood Pharmaceuticals, INC | $46.23 | 2023-2024 | Linzess |
| Abbvie INC. | $44.56 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $40.55 | 2023 | |
| Qol Medical, LLC | $36.03 | 2024 | Sucraid |
| Gilead Sciences, INC. | $31.41 | 2023-2024 | |
| Lilly USA, LLC | $17.37 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $16.42 | 2024 | |
| Ardelyx, INC. | $16.35 | 2024 | Ibsrela |
| Laborie Medical Technologies Corp. | $14.16 | 2023 | |
| Cook Medical LLC | $12.59 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Infantolino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.